Enjolras, O., Wassef, M., Mazoyer, E., et al. Infants with Kasabach–Merritt syndrome do not have “true” hemangiomas. J Pediatr 130 (1997), 631–640.
Enjolras, O., Mulliken, J.B., Wassef, M., et al. Residual lesions after Kasabach–Merritt phenomenon in 41 patients. J Am Acad Dermatol 42 (2000), 225–235.
Sarkar, M., Mulliken, J., Kozakewich, H., et al. Thrombocytopenic Coagulopathy (Kasabach–Merritt Phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 100 (1997), 1377–1386.
Wong, B., Lee, V., Tikka, T., et al. Kaposiform haemangioendothelioma of the head and neck. Crit Rev Oncol Hematol 104 (2016), 156–168.
Drolet, B., Trenor, C., Brandao, L., et al. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma. J Pediatr 163 (2013), 285–291.
Croteau, S., Liang, M., Kazakewich, H., et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach–Merritt Phenomenon in 107 referrals. J Pediatr 162 (2013), 142–147.
Boccara, O., Fraitag, S., Lasne, D., et al. Kaposiform haemangioendothelioma-spectrum Lesions with Kasabach–Merritt Phenomenon: retrospective analysis and long-term outcome. Acta Derm Venereol 96 (2016), 77–81.
Ryu, Y., Choi, Y., Cheon, J., et al. Imaging findings of Kaposiform hemangioendothelioma in children. Eur J Radiol 86 (2017), 198–205.
Wassef, M., Blei, F., Adams, D., et al. ISSVA board and scientific committee. Vascular anomalies classification: recommendations from the International Society for the study of vascular anomalies. Pediatrics 136 (2015), 203–214.
Reichel, A., Hamm, H., Wiegering, V., et al. Kaposiform hemangioendothelioma with Kasabach–Merritt syndrome: successful treatment with sirolimus. J Dtsch Dermatol Ges 15 (2017), 329–331.
Pascal, S., Bettex, Q., Andre, N., et al. Successful surgical management of congenital Kasabach–Merritt syndrome. Pediatr Int 59 (2017), 89–102.
Boccara, O., Maruani, A., Léauté-Labrèze, C., Anomalies vasculaires bénignes agressives de l'enfant et de l'adolescent. Bull Cancer 105 (2018), 610–625.
Rodriguez, V., Lee, A., Witman, P., et al. Kasabach–Merritt Phenomenon. Case series and retrospective review of the Mayo Clinic Experience. J Pediatr Hematol Oncol 31 (2009), 522–526.
Thirion, S., Jamblin, P., Demarche, M., et al. A new treatment for vascular anomalies: six cases treated with rapamycin. Arch Pediatr 24 (2017), 600–606.
Lackner, H., Karastaneva, A., Schwinger, W., et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 174 (2015), 1579–1584.
Blatt, J., Stavas, J., Moats-Staats, et al. Treatment of childhood Kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 55 (2010), 1396–1398.
Wang, H., Duan, Y., Gao, Y., et al. Sirolimus for vincristine-resistant Kasabach–Merritt Phenomenon: report of eight patient. Pediatr Dermatol 34 (2017), 261–265.
Hammill, A., Wentzel, M.S., Gupta, A., et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 57 (2011), 1018–1024.
Ji, Y., Chen, S., Xiang, B., et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer 141 (2017), 848–855.
Chiu, Y., Drolet, B., Blei, F., et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon. Pediatr Blood Cancer 59 (2012), 934–938.
Hermans, D., van Beynum, I., van der Vijver, R., et al. Kaposiform hemangioendothelioma with Kasabach–Merritt syndrome: a new indication for propranolol treatment. J Pediatr Hematol Oncol 33 (2011), 171–173.
